Nuformix plc announced the appointment of Dr. Anne Brindley as Executive Director of the Company with immediate effect. Anne has over 30 years' experience in Big Pharma, Biotech and smaller R&D companies, with a proven international track record of leading organizations through strategic change and driving projects and portfolios through discovery and development to market. Before moving to Advent, Anne was a Board member and Managing Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals (part of Johnson & Johnson, Inc), where she was responsible for leadership and operations of the company, including discovery /development programmes spanning three novel classes of drug for idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and asthma, as well as out-licensing activities. Prior to this, Anne occupied the role of Vice President and Head of Inhalation Products.